Fette Compacting and Glatt Partner to Develop Continuous Manufacturing Solutions

News
Article

Fette Compacting and Glatt have joined forces to develop integrated solutions for the continuous manufacturing of oral solid-dosage drug forms.

Fette Compacting, which produces tablet compression equipment, and Glatt, which specializes in powder processing and tablet coating, have joined forces to develop integrated solutions for the continuous manufacturing of oral solid dosage (OSD) forms, the companies announced in a Nov. 28, 2017 press release. The new offering combines the know-how and experience of Fette Compacting and Glatt in the areas of pharmaceutical process technology and equipment design to provide OSD drug manufacturers with continuous manufacturing solutions for formulation development, clinical trials, and pilot and commercial production.

“Our aim is to jointly develop a technology platform for continuous manufacturing of OSD that outperforms the competition in terms of process robustness, product quality and yield, efficiency, productivity, and operator safety,” said Fette Compacting CEO Olaf J. Müller in the press release.

At the P-MEC 2018 trade fair in Mumbai, India, the two companies exhibited the first continuous line resulting from the cooperation. In the future, the two companies will focus on the development of comprehensive integrated solutions for direct compression and granulation-based continuous manufacturing lines, including advanced process control systems. Beginning in February 2018, Glatt and Fette Compacting will offer customer trials for continuous direct compression and continuous wet granulation in Pune, India in a new test facility.

Source: Fette Compacting

Recent Videos
Miguel Forte from ISCT and Kiji Therapeutics talks about the potential impact of a changing European political landscape.
Miguel Forte from ISCT and Kiji Therapeutics provides his insights into the changing political landscape in the US as well as legislative and regulatory adjustments
Miguel Forte from ISCT and Kiji Therapeutics chats about expectations for 2025 and the future technology agenda for industry.
Sheryl Johnson from Orbia Fluor & Energy Materials chats about gender diversity, how women are helping to advance innovation, sustainability challenges, and progress in the field of inhaled drugs.
Mike Baird from Schlafender Hase gives his predictions for how AI and ML may find use in the industry moving forwards and provides some predictions about M&A and the changing US government administration.
Mike Baird from Schlafender Haser discusses industry trends from 2024 and those expected to have an impact in 2025 from the perspective of a software developer.
Preeya Beczek from Beczek.COM gives her thoughts on the areas to watch with the new US administration and how Europe might be finalizing preparations for previous legislative changes
Related Content